Skip to main content
SpringerLink
Log in

Inolimomab

Anti-CD25 Monoclonal Antibody B-B10, Anti-interleukin-2 Receptor Monoclonal Antibody B-B10, B-B10, BT 563, Leukotac®

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Van Gelder T, Zietse R, Mulder AH, et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995 Aug 15; 60: 248–52

    Article  PubMed  Google Scholar 

  2. Hertenstein B, Stefanic M, Sandherr M, et al. Treatment of steroid- resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563). Transplant Proc 1994 Dec; 26: 3114–6

    PubMed  CAS  Google Scholar 

  3. Neuhaus P, Bechstein WO, Blumhardt G, et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993 Jun; 55: 1320–7

    Article  PubMed  CAS  Google Scholar 

  4. Nashan B, Schlitt HJ, Schwinzer R, et al. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Transplantation 1996 Feb 27; 61: 546–54

    Article  PubMed  CAS  Google Scholar 

  5. Langrehr JM, Nüssler NC, Neumann U, et al. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation 1997 Jun 27; 63: 1772–81

    Article  PubMed  CAS  Google Scholar 

  6. Carl S, Wiesel M, Daniel V, et al. Rescue therapy with interleukin-2 receptor antibody in high risk kidney transplant patients: a 3-year follow-up study. Transplant Proc 1997 Feb–Mar; 29: 320–2

    Article  PubMed  CAS  Google Scholar 

  7. Hesse CJ, Vangelder T, Vaessen LMB, et al. Pharmacodynamics of prophylactic antirejection therapy with an anti-interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation. Immunopharmacology 1995 Sep; 30: 237–46

    Article  PubMed  CAS  Google Scholar 

  8. Cuthbert RJG, Phillips GL, Barnett MJ, et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant 1992 Nov; 10: 451–5

    PubMed  CAS  Google Scholar 

  9. Van Gelder T, Mulder AH, Balk AHMM, et al. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients. J Heart Lung Transplant 1995 Mar–Apr; 14: 346–50

    PubMed  Google Scholar 

  10. Van Gelder T, Baan CC, Balk AHMM, et al. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans. Transplantation 1998 Feb 15; 65: 405–10

    Article  PubMed  Google Scholar 

  11. van Gelder T, Zietse R, Yzermans JNM, et al. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial. Transplant Proc 1996 Dec; 28: 3221–2

    PubMed  Google Scholar 

  12. Wiesel M, Carl S, Pomer S, et al. Effect of the anti-IL2 receptor monoclonal antibody inolimomab in treatment of acute interstitial renal rejection. J Urol 1995 Apr; 153 Suppl.: 399

    Article  Google Scholar 

  13. Langrehr JM, Guckelberger O, Nüssler N, et al. Interleukin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: a randomized study. Transplant Proc 1996 Dec; 28: 3204

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Inolimomab. Drugs R&D 1, 81–84 (1999). https://doi.org/10.2165/00126839-199901010-00027

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901010-00027

Keywords

Search

Navigation